NZ709635A - Bcl-2bcl-xl inhibitors and therapeutic methods using the same - Google Patents
Bcl-2bcl-xl inhibitors and therapeutic methods using the sameInfo
- Publication number
- NZ709635A NZ709635A NZ70963514A NZ70963514A NZ709635A NZ 709635 A NZ709635 A NZ 709635A NZ 70963514 A NZ70963514 A NZ 70963514A NZ 70963514 A NZ70963514 A NZ 70963514A NZ 709635 A NZ709635 A NZ 709635A
- Authority
- NZ
- New Zealand
- Prior art keywords
- bcl
- inhibitors
- same
- 2bcl
- therapeutic methods
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 abstract 4
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 abstract 4
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 abstract 2
- 229940122035 Bcl-XL inhibitor Drugs 0.000 abstract 2
- 229940123711 Bcl2 inhibitor Drugs 0.000 abstract 2
- VNMNSTIGSQBDPI-UHFFFAOYSA-N 2,3-diphenyl-1h-pyrrole Chemical group N1C=CC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 VNMNSTIGSQBDPI-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361753066P | 2013-01-16 | 2013-01-16 | |
| PCT/US2014/011571 WO2014113413A1 (en) | 2013-01-16 | 2014-01-15 | Bcl-2bcl-xl inhibitors and therapeutic methods using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ709635A true NZ709635A (en) | 2019-10-25 |
Family
ID=51165292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ70963514A NZ709635A (en) | 2013-01-16 | 2014-01-15 | Bcl-2bcl-xl inhibitors and therapeutic methods using the same |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9096625B2 (enExample) |
| EP (2) | EP2945940B1 (enExample) |
| JP (1) | JP6347793B2 (enExample) |
| KR (2) | KR102318204B1 (enExample) |
| CN (3) | CN110305162A (enExample) |
| AU (1) | AU2014207716B2 (enExample) |
| CA (1) | CA2897055C (enExample) |
| ES (1) | ES2819232T3 (enExample) |
| HK (1) | HK1219734A1 (enExample) |
| NZ (1) | NZ709635A (enExample) |
| SG (1) | SG11201505525UA (enExample) |
| WO (1) | WO2014113413A1 (enExample) |
| ZA (1) | ZA201504902B (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6347793B2 (ja) * | 2013-01-16 | 2018-06-27 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | Ｂｃｌ−２／Ｂｃｌ−ｘＬ阻害薬およびそれを使用した治療方法 |
| IL311537A (en) | 2014-01-28 | 2024-05-01 | Mayo Found Medical Education & Res | Methods and preparations for killing aging cells and for the treatment of diseases and disorders related to aging |
| EP3139942B1 (en) | 2014-05-05 | 2019-12-18 | Bioventures, Llc | COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS |
| US10071087B2 (en) | 2014-07-22 | 2018-09-11 | Bioventures, Llc | Compositions and methods for selectively depleting senescent cells |
| WO2016127135A1 (en) * | 2015-02-06 | 2016-08-11 | Unity Biotechnology, Inc. | Compounds and uses in treatment of senescence-associated conditons |
| US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| US11111259B2 (en) | 2015-12-18 | 2021-09-07 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
| KR102494039B1 (ko) | 2016-03-28 | 2023-01-30 | 프레시지 바이오싸이언시스, 인크. | 암 치료를 위한 제약학적 조합물 |
| US10807977B2 (en) | 2016-04-21 | 2020-10-20 | Bioventures, Llc | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof |
| CN106177955B (zh) * | 2016-08-18 | 2018-03-16 | 广州威溶特医药科技有限公司 | Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
| WO2018098534A1 (en) * | 2016-12-02 | 2018-06-07 | Garvan Institute Of Medical Research | Methods of treating cancer and reagents thereof |
| EP3441069B1 (en) | 2017-08-11 | 2023-04-05 | Unity Biotechnology, Inc. | Treatment of diabetic retinopathy using pharmaceutical agents that eliminate senescent cells |
| US20200354336A9 (en) * | 2017-08-11 | 2020-11-12 | Unity Biotechnology, Inc. | Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells |
| WO2019033122A1 (en) * | 2017-08-11 | 2019-02-14 | Unity Biotechnology, Inc. | TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
| US10588916B2 (en) | 2017-10-31 | 2020-03-17 | Unity Biotechnology, Inc. | Technology to inhibit vascular changes that lead to vision loss in the eye |
| AU2018357829B2 (en) | 2017-12-30 | 2019-09-26 | Unity Biotechnology, Inc. | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer |
| SG11202005785XA (en) | 2018-01-10 | 2020-07-29 | Recurium Ip Holdings Llc | Benzamide compounds |
| ES3041854T3 (en) * | 2018-01-22 | 2025-11-17 | Bioventures Llc | Bcl-2 proteins degraders for cancer treatment |
| HUE071493T2 (hu) | 2018-04-29 | 2025-09-28 | Beigene Switzerland Gmbh | Bcl-2 inhibitorok |
| CA3056878C (en) | 2018-04-30 | 2021-03-30 | Unity Biotechnology | Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| US10738042B2 (en) | 2018-04-30 | 2020-08-11 | Unity Biotechnology, Inc. | Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| CN112513057B (zh) | 2018-04-30 | 2024-01-05 | 联合生物科技公司 | 供在由衰老细胞引起或介导的状况的临床管理中使用和用于治疗癌症的作为Bcl家族拮抗剂的酰基氨基膦酸酯和酰基苄胺 |
| US12084423B2 (en) | 2018-05-18 | 2024-09-10 | Bioventures, Llc | Piperlongumine analogues and uses thereof |
| US10717722B2 (en) | 2018-06-13 | 2020-07-21 | Unity Biotechnology, Inc. | Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| CN110776507B (zh) | 2018-07-31 | 2020-12-18 | 苏州亚盛药业有限公司 | Bcl-2抑制剂与化疗药的组合产品及其在预防和/或治疗疾病中的用途 |
| EP3672591B1 (en) | 2018-07-31 | 2024-02-14 | Ascentage Pharma (Suzhou) Co., Ltd. | Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/or bendamustine or bcl-2 inhibitor combined with chop |
| BR112020018978A2 (pt) | 2018-07-31 | 2021-03-02 | Ascentage Pharma (Suzhou) Co., Ltd. | produto de combinação que compreende um inibidor de bcl-2 e um inibidor de mdm2 e uso dos ditos inibidores na prevenção e/ou tratamento de câncer |
| US12083136B2 (en) | 2018-07-31 | 2024-09-10 | Ascentage Pharma (Suzhou) Co., Ltd | Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof |
| CN114522167A (zh) * | 2018-07-31 | 2022-05-24 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| US11491168B2 (en) | 2018-07-31 | 2022-11-08 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof |
| US12220419B2 (en) | 2018-08-22 | 2025-02-11 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
| US11872237B2 (en) * | 2018-12-28 | 2024-01-16 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical composition and preparation method thereof |
| TWI729662B (zh) * | 2019-01-04 | 2021-06-01 | 大陸商蘇州亞盛藥業有限公司 | 一種磺胺類化合物及製備磺胺類化合物的製程 |
| EP3906235B1 (en) * | 2019-01-04 | 2023-03-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Method for preparing sulfonamides drugs |
| TWI770503B (zh) * | 2019-05-13 | 2022-07-11 | 大陸商蘇州亞盛藥業有限公司 | 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物 |
| TW202114692A (zh) * | 2019-07-02 | 2021-04-16 | 大陸商蘇州亞盛藥業有限公司 | 一種含有mTOR抑制劑的藥物組合及其應用 |
| US12370197B2 (en) * | 2019-07-31 | 2025-07-29 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| WO2021066873A1 (en) | 2019-10-03 | 2021-04-08 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| WO2021078301A1 (zh) * | 2019-10-24 | 2021-04-29 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
| WO2021104442A1 (en) * | 2019-11-27 | 2021-06-03 | Ascentage Pharma (Suzhou) Co., Ltd. | Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway |
| CN112891353B (zh) * | 2019-12-04 | 2024-01-30 | 苏州亚盛药业有限公司 | 药物组合及其用途 |
| CN114786654A (zh) * | 2019-12-11 | 2022-07-22 | 密执安大学评议会 | 用于全身递送Bcl-2和Bcl-xL拮抗剂的组合物和方法 |
| CN113350281B (zh) * | 2020-03-02 | 2023-08-15 | 苏州亚盛药业有限公司 | 载药聚合物胶束及其制剂和制备方法 |
| EP3914257B1 (en) * | 2020-04-10 | 2023-12-27 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of a bcl-2/bcl-xl inhibitor with osimertinib |
| BR112022019525A2 (pt) | 2020-04-15 | 2023-11-14 | Beigene Ltd | Composto, composição farmacêutica e método para tratar doenças apoptóticas desreguladas |
| WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
| WO2022008464A1 (en) | 2020-07-06 | 2022-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
| WO2022012481A1 (en) * | 2020-07-13 | 2022-01-20 | Ascentage Pharma (Suzhou) Co., Ltd. | Crystalline or Amorphous form of Bcl-2/Bcl-xL inhibitor compound or its salts |
| CN114053288B (zh) * | 2020-07-31 | 2024-11-19 | 苏州亚盛药业有限公司 | 肺部疾病治疗的组合物和方法 |
| CA3199345A1 (en) * | 2020-11-10 | 2022-05-19 | Unity Biotechnology, Inc. | Crystalline solid meglumine salt inhibitor of bcl and methods of making and using same |
| WO2022111647A1 (en) * | 2020-11-27 | 2022-06-02 | Ascentage Pharma (Suzhou) Co., Ltd. | Formulation combination containing freeze-dried formulation and reconstituted solvent, preparation method and application thereof |
| WO2022120114A1 (en) | 2020-12-04 | 2022-06-09 | University Of Notre Dame Du Lac | Method of encapsulating single cells utilizing an alternating current electrospray |
| EP4382126A4 (en) * | 2021-08-02 | 2025-07-30 | Ascentage Pharma Suzhou Co Ltd | PHARMACEUTICAL COMBINATION AND ITS USE |
| TW202415653A (zh) * | 2022-08-02 | 2024-04-16 | 大陸商北京星奇原生物科技有限公司 | Ｂｃｌ－ｘｌ降解化合物 |
| WO2024051741A1 (zh) * | 2022-09-06 | 2024-03-14 | 西藏海思科制药有限公司 | 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用 |
| WO2024245312A1 (en) * | 2023-05-30 | 2024-12-05 | Ascentage Pharma (Suzhou) Co., Ltd. | Bcl-2/bcl-xl protein degrader and use thereof |
| WO2025087879A2 (en) | 2023-10-23 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7432304B2 (en) | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| CA2577752A1 (en) | 2004-08-20 | 2006-03-02 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
| TWI337608B (en) | 2005-05-12 | 2011-02-21 | Abbott Lab | Apoptosis promoters |
| US20070197532A1 (en) | 2005-11-18 | 2007-08-23 | Cao Sheldon X | Glucokinase activators |
| MX2009002422A (es) * | 2006-09-05 | 2009-03-20 | Abbott Lab | Inhibidores bcl para tratar exceso de plaquetas. |
| JP5385382B2 (ja) | 2008-07-24 | 2014-01-08 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | プロテインキナーゼ阻害剤としての３，４−ジアリールピラゾール |
| US20100278921A1 (en) | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| SG192126A1 (en) * | 2011-01-25 | 2013-09-30 | Univ Michigan | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
| JP6347793B2 (ja) * | 2013-01-16 | 2018-06-27 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | Ｂｃｌ−２／Ｂｃｌ−ｘＬ阻害薬およびそれを使用した治療方法 |
-
2014
- 2014-01-15 JP JP2015553788A patent/JP6347793B2/ja active Active
- 2014-01-15 CN CN201910634723.XA patent/CN110305162A/zh active Pending
- 2014-01-15 KR KR1020207037597A patent/KR102318204B1/ko active Active
- 2014-01-15 EP EP14741180.5A patent/EP2945940B1/en active Active
- 2014-01-15 SG SG11201505525UA patent/SG11201505525UA/en unknown
- 2014-01-15 EP EP20163914.3A patent/EP3689886A1/en not_active Withdrawn
- 2014-01-15 AU AU2014207716A patent/AU2014207716B2/en active Active
- 2014-01-15 KR KR1020157021823A patent/KR102210316B1/ko active Active
- 2014-01-15 WO PCT/US2014/011571 patent/WO2014113413A1/en not_active Ceased
- 2014-01-15 NZ NZ70963514A patent/NZ709635A/en unknown
- 2014-01-15 ES ES14741180T patent/ES2819232T3/es active Active
- 2014-01-15 US US14/155,809 patent/US9096625B2/en active Active
- 2014-01-15 CN CN201910634742.2A patent/CN110302205B/zh active Active
- 2014-01-15 CA CA2897055A patent/CA2897055C/en active Active
- 2014-01-15 HK HK16107756.1A patent/HK1219734A1/zh unknown
- 2014-01-15 CN CN201480015733.0A patent/CN105246882A/zh active Pending
-
2015
- 2015-07-08 ZA ZA2015/04902A patent/ZA201504902B/en unknown
- 2015-08-03 US US14/816,191 patent/US9403856B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9403856B2 (en) | 2016-08-02 |
| EP3689886A1 (en) | 2020-08-05 |
| KR102210316B1 (ko) | 2021-01-29 |
| ZA201504902B (en) | 2016-07-27 |
| JP2016506916A (ja) | 2016-03-07 |
| WO2014113413A1 (en) | 2014-07-24 |
| CN105246882A (zh) | 2016-01-13 |
| AU2014207716A1 (en) | 2015-07-23 |
| CA2897055C (en) | 2021-04-20 |
| JP6347793B2 (ja) | 2018-06-27 |
| KR102318204B1 (ko) | 2021-10-26 |
| EP2945940B1 (en) | 2020-07-15 |
| SG11201505525UA (en) | 2015-08-28 |
| US20150336994A1 (en) | 2015-11-26 |
| AU2014207716B2 (en) | 2017-07-27 |
| ES2819232T3 (es) | 2021-04-15 |
| EP2945940A4 (en) | 2016-07-06 |
| CN110302205B (zh) | 2020-06-09 |
| KR20150104631A (ko) | 2015-09-15 |
| HK1219734A1 (zh) | 2017-04-13 |
| CN110302205A (zh) | 2019-10-08 |
| US20140199234A1 (en) | 2014-07-17 |
| CA2897055A1 (en) | 2014-07-24 |
| EP2945940A1 (en) | 2015-11-25 |
| US9096625B2 (en) | 2015-08-04 |
| KR20210002126A (ko) | 2021-01-06 |
| CN110305162A (zh) | 2019-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ709635A (en) | Bcl-2bcl-xl inhibitors and therapeutic methods using the same | |
| MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
| WO2012103059A3 (en) | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same | |
| PH12016500024A1 (en) | Bromodomain inhibitor | |
| MX2015010125A (es) | Derivados de piridazinona-amidas. | |
| MX366130B (es) | Inhibidores bivalentes de las proteinas iap y métodos terapéuticos que usan los mismos. | |
| MX2021001186A (es) | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. | |
| PH12015502161A1 (en) | Therapeutic compounds and compositions | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| PH12015501576A1 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| MX2015006478A (es) | Inhibidores de glutaminasa y metodos de empleo. | |
| MX2016001037A (es) | Inhibidores de factores de transcripción y usos. | |
| MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
| IN2015DN01156A (enExample) | ||
| EP4230264A3 (en) | Prodrugs of fumarates and their use in treating various deseases | |
| MX2016006432A (es) | Tetrahidro-benzodiazepinonas. | |
| MX2016004678A (es) | Composiciones para el tratamiento del cancer. | |
| MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| MX2014003376A (es) | Derivados de acido benzoico como inhibidores eif4e. | |
| MX2016001136A (es) | Derivados de oxoquinazolinil-butanamida. | |
| NZ628433A (en) | Chitosan-derived compositions | |
| CA2929436C (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
| TW201613578A (en) | Pharmaceutical combinations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JAN 2022 BY BIRGIT KNAACK Effective date: 20210107 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JAN 2023 BY BIRGIT KNAACK Effective date: 20211208 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JAN 2024 BY PAVIS PAYMENT GMBH Effective date: 20230111 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JAN 2025 BY BIRGIT KNAACK Effective date: 20231228 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JAN 2026 BY BIRGIT KNAACK Effective date: 20250102 |